Abstract:The high incidence of mutations and the crucial roles of KAT2A in cancer development have received increased attention. Nevertheless, a systematic comparison of the heterogeneity and dynamics across different cancer types has not been conducted. Hence, a deep analysis using public databases was performed to clarify the contributions of KAT2A and its correlation with tumorigenesis. The raw data regarding KAT2A expression in cancer patients and healthy controls were obtained from The Cancer Genome Atlas (TCGA). Sexually dimorphic manner, genomic alterations, and expression pattern of KAT2A, as well as the association of the KAT2A with survival, were retrieved from UALCAN, cBioportal, and TISIDB databases. Additionally, the Protein-Protein Interaction (PPI) analysis was conducted using the STRING database. The human protein atlas was used to obtain the staining results of protein levels in cancer and normal samples. The correlation between KAT2A and its potential target drugs was determined using TISIDB and HISTome2. Compared to the normal tissues, CHOL and TGCT tumors presented significantly high KAT2A expression, which was positively correlated with BLCA, BRCA, CESC, CHOL, COAD, ESCA, HNSC, KICH, KIRP, LIHC, LUAD, LUSC, READ, STAD, and THCA. However, no significant difference was detected between normal and tumor tissues for the sex difference pattern of KAT2A expression. The PPI analysis indicated that TADA3, CCDC101, TRRAP, SUPT3H, MYC, TADA2A, and USP22 levels were positively correlated with KAT2A expression, while TADA2B and ATXN7 were negatively correlated. A positive link of KAT2A with cancer isotypes and significant connections of the KAT2A expression to poor overall and disease-free survival were also observed. Further validation was conducted using immunohistochemistry (IHC) staining, qPCR, and Western blot. Some potential HAT inhibitory drugs of KAT2A were also determined, but more work and clinical trials are required before their application.

KAT2A succinyltransferase activity-mediated 14-3-3ζ upregulation promotes β-catenin stabilization-dependent glycolysis and proliferation of pancreatic carcinoma cells.

KAT2A Promotes the Succinylation of PKM2 to Inhibit its Activity and Accelerate Glycolysis of Gastric Cancer

Histone acetyltransferase 1 is a succinyltransferase for histones and non‐histones and promotes tumorigenesis

Polycomb Protein Ezh2 Activates Wnt/Beta-Catenin Signaling To Promote Hepatocellular Carcinoma Development

Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma

Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth

ACSS2 Acts As a Lactyl-Coa Synthetase and Couples KAT2A to Function As a Lactyltransferase for Histone Lactylation and Tumor Immune Evasion

KAT2A coupled with the α-KGDH complex acts as a histone H3 succinyltransferase

KAT7 enhances the proliferation and metastasis of head and neck squamous carcinoma by promoting the acetylation level of LDHA

KAT6A, a Novel Regulator of Β-Catenin, Promotes Tumorigenicity and Chemoresistance in Ovarian Cancer by Acetylating COP1

Integrative analysis of histone acetyltransferase KAT2A in human cancer

BCAT2-mediated BCAA Catabolism is Critical for Development of Pancreatic Ductal Adenocarcinoma.

CCT6A facilitates lung adenocarcinoma progression and glycolysis via STAT1/HK2 axis

Acetyltransferase P300 Regulates Glucose Metabolic Reprogramming through Catalyzing Succinylation in Lung Cancer

SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells

KAT5 promotes invasion and metastasis through C-MYC stabilization in ATC.

TCF7L2 Positively Regulates Aerobic Glycolysis Via the EGLN2/HIF-1α Axis and Indicates Prognosis in Pancreatic Cancer

KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.

KIF2C Facilitates Tumor Growth and Metastasis in Pancreatic Ductal Adenocarcinoma

Kindlin-2 enhances c-Myc translation through association with DDX3X to promote pancreatic ductal adenocarcinoma progression

EPAS1 promote tumor progression by interacting with Wnt/β-catenin signaling in pancreatic cancer